Amgen's gastric cancer drug meets late-stage trial goal-February 2024-www.financetom.com

Amgen's gastric cancer drug meets late-stage trial goal

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Amgen's gastric cancer drug meets late-stage trial goal

Jun 30, 2025 6:29 AM

June 30 (Reuters) - Amgen ( AMGN ) said on Monday its

experimental cancer therapy, when combined with chemotherapy,

met the main goal in a late-stage trial.

Previous page： Gujarat Pipavav Port expects first and second quarters of FY24 to be weak Next page： Zee Ent Q4: Margins collapse, weak ad environment, Rs 73 cr net loss.....Troubles aplenty for the broadcaster

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Gujarat Pipavav Port expects first and second quarters of FY24 to be weak

May 25, 2023

Trades in Asia and America have decelerated. Within India as well, trade is low, says Aggarwal. But is expected to improve in second half of FY23.

Zee Ent Q4: Margins collapse, weak ad environment, Rs 73 cr net loss.....Troubles aplenty for the broadcaster

May 25, 2023

EBITDA margins have collapsed to single digits. The fourth quarter clocked 7.2 percent EBITDA margins compared with 21 percent in same quarter of last year. The management attributes the weak performance to soft advertising environment, negligible subscription growth and high investments in its OTT platform, Zee5.

Bharat Dynamics Q4: 500 bps margin decline, Net profits fall 42 percent

May 25, 2023

Delays in receipt of certain electronic components and explosives from foreign OEMs has impacted the performance during FY23 and the company is exploring alternatives to mitigate the impact.

LIC looking at profitable growth in market share: Chairperson Siddhartha Mohanty

May 25, 2023

The LIC Chairman noted that the insurer will also maintain its current growth rate for embedded value. LIC's EV is Rs 5.82 lakh crore now and the company has shown a growth rate of 7.59 percent year-on-year